Interestingly, delivery of Nrtn using adeno associated viral (AAV) vectors has been tested in human PD, and nonclinical translational experiments to test the safety, feasibility and effectiveness of targeting the SN with AAV2-Nrtn to support clinical studies to enhance the trophic response in PD DA neurons [27]. Here, NRTN is linked to Parkinson disease.